Literature DB >> 18552699

The effects of estrogen on pulmonary artery vasoreactivity and hypoxic pulmonary vasoconstriction: potential new clinical implications for an old hormone.

Tim Lahm1, Paul R Crisostomo, Troy A Markel, Meijing Wang, Brent R Weil, Nathan M Novotny, Daniel R Meldrum.   

Abstract

BACKGROUND AND OBJECTIVES: Recent research recognizes gender as a major factor determining the outcomes in trauma, ischemia/reperfusion, shock, and sepsis. In particular, estrogen has been demonstrated to exert protective effects in these settings. The effects of estrogens on the pulmonary vasculature are potent and complex yet not fully understood. A better mechanistic understanding may allow for future therapeutic interventions in pulmonary hypertensive crises after cardiac surgery and during acute lung injury as well as in patients with pulmonary arterial hypertension. DATA SOURCES AND STUDY SELECTION: We searched PubMed for articles in the English language by using the search words pulmonary hypertension, hypoxic pulmonary vasoconstriction, estrogen, estradiol, inflammation, acute injury, ischemia reperfusion, sepsis, trauma, and burns. These were used in various combinations. We read the abstracts of the relevant titles to confirm their relevance, and the full articles were then extracted. References from extracted articles were checked for any additional relevant articles. DATA EXTRACTION AND SYNTHESIS: Estrogen plays a critical role in the improved outcomes in the settings of trauma, shock, sepsis, myocardial ischemia/reperfusion, and acute lung injury. Several new mechanisms of action have been identified. In the pulmonary vasculature, estrogen causes vasodilation and attenuates the vasoconstrictor response to various stimuli, including hypoxia. This is mediated by increased levels of prostacyclin and nitric oxide as well as decreased levels of endothelin-1. In addition, effects on intracellular signaling pathways and several kinases as well as anti-inflammatory mechanisms may contribute as well. Recent studies suggest the importance of acute, nongenomic effects.
CONCLUSION: Estrogen exerts a variety of nongenomic actions, which may allow for future therapeutic interventions in pulmonary vascular disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18552699     DOI: 10.1097/CCM.0b013e31817d1a92

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  26 in total

Review 1.  The effects of estrogen on various organs: therapeutic approach for sepsis, trauma, and reperfusion injury. Part 1: central nervous system, lung, and heart.

Authors:  Takashi Kawasaki; Irshad H Chaudry
Journal:  J Anesth       Date:  2012-06-23       Impact factor: 2.078

Review 2.  Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure.

Authors:  James Hester; Corey Ventetuolo; Tim Lahm
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

3.  The sexual dimorphism associated with pulmonary hypertension corresponds to a fibrotic phenotype.

Authors:  Olga Rafikova; Ruslan Rafikov; Mary Louise Meadows; Archana Kangath; Danny Jonigk; Stephen M Black
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

4.  17β-Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects.

Authors:  Tim Lahm; Marjorie Albrecht; Amanda J Fisher; Mona Selej; Neel G Patel; Jordan A Brown; Matthew J Justice; M Beth Brown; Mary Van Demark; Kevin M Trulock; Dino Dieudonne; Jagadeshwar G Reddy; Robert G Presson; Irina Petrache
Journal:  Am J Respir Crit Care Med       Date:  2012-03-01       Impact factor: 21.405

5.  Estrogen rescues preexisting severe pulmonary hypertension in rats.

Authors:  Soban Umar; Andrea Iorga; Humann Matori; Rangarajan D Nadadur; Jingyuan Li; Federica Maltese; Arnoud van der Laarse; Mansoureh Eghbali
Journal:  Am J Respir Crit Care Med       Date:  2011-06-23       Impact factor: 21.405

Review 6.  Sex differences and sex steroids in lung health and disease.

Authors:  Elizabeth A Townsend; Virginia M Miller; Y S Prakash
Journal:  Endocr Rev       Date:  2012-01-12       Impact factor: 19.871

7.  Interaction between bone morphogenetic protein receptor type 2 and estrogenic compounds in pulmonary arterial hypertension.

Authors:  Joshua P Fessel; Xinping Chen; Andrea Frump; Santhi Gladson; Tom Blackwell; Christie Kang; Jennifer Johnson; James E Loyd; Anna Hemnes; Eric Austin; James West
Journal:  Pulm Circ       Date:  2013-12-02       Impact factor: 3.017

Review 8.  Molecular pathogenesis and current pathology of pulmonary hypertension.

Authors:  Vinicio A de Jesus Perez
Journal:  Heart Fail Rev       Date:  2016-05       Impact factor: 4.214

9.  Dominant Role for Regulatory T Cells in Protecting Females Against Pulmonary Hypertension.

Authors:  Rasa Tamosiuniene; Olga Manouvakhova; Paul Mesange; Toshie Saito; Jin Qian; Mrinmoy Sanyal; Yu-Chun Lin; Linh P Nguyen; Amir Luria; Allen B Tu; Joshua M Sante; Marlene Rabinovitch; Desmond J Fitzgerald; Brian B Graham; Aida Habtezion; Norbert F Voelkel; Laure Aurelian; Mark R Nicolls
Journal:  Circ Res       Date:  2018-03-15       Impact factor: 17.367

10.  Acute postischemic treatment with estrogen receptor-alpha agonist or estrogen receptor-beta agonist improves myocardial recovery.

Authors:  Nicholas D Vornehm; Meijing Wang; Aaron Abarbanell; Jeremy Herrmann; Brent Weil; Jiangjing Tan; Yue Wang; Megan Kelly; Daniel R Meldrum
Journal:  Surgery       Date:  2009-08       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.